Recent developments in immunogenicity assays from a CRO perspective
Due to the increasing complexity of modern biotherapeutics, in-depth immunogenicity assessments are needed to thoroughly investigate the immune response that different modalities — whether those are cell-based drugs, antibody-drug conjugates, multi-specific antibodies or oligonucleotides — elicit. In this resource, ICON provides their insights into immunogenicity assessments for cell-based biotherapeutics and multidomain antibody therapeutics, as well as using an LBA / LC–MS/MS hybrid approach.
This resource is part of the Bioanalysis Zone Spotlight on immunogenicity assessment of therapeutic proteins. Click here to view the full feature.
In association with:
